Last week, the European Specialist Nurses Organisations (ESNO) released a document aimed at assisting nurses in the management of switching a patient from a reference biologic to a biosimilar.
Last week, the European Specialist Nurses Organisations (ESNO) released a document aimed at assisting nurses in the management of switching a patient from a reference biologic to a biosimilar. The guidelines specifically address the role of specialized nurse interactions with patients during the switching process and build upon existing European Commission guidelines for the healthcare community.
“Switching between similar biological medicines needs good management. Nurses play a crucial role in communicating with patients and providing support and reassurance, before, during, and after the switch,” said Ber Oomen, executive director at ESNO, in a statement.
Nurses have firsthand experience in leading the transition between a reference biologic and a biosimilar. In order to address the important interactions nurses have with patients, the guidelines include points around how to better inform and clearly communicate information about biologics and biosimilars.
Specifically, the guidelines contain talking points around the benefits of biosimilars such as increasing patient access to drugs, how to address patient questions or concerns if they are hesitant about switching, and exercising proper pharmacovigilance.
In addition, there are multiple case studies and real-world data included in the document that reinforce biosimilars' safe and effective use. “The quality, safety, and efficacy of biosimilar medicines are assessed and tested with comparability studies (including clinical trials) before the medicine is approved,” read the guidelines.
The guide was created by the ESNO community “based on similar initiatives across Eruope where switching programs are already in place.” For convenience, the authors also created a pocket dictionary for nurses that includes frequently asked questions from patients and how to address them.
“This is built on nurses’ many years of education, and their experience with patients in different therapies. It is a process that requires time, patience, and care… Patients need to know that their healthcare professionals understand the reasoning behind the switch and are confident that it is the right thing to do. This guide aims to achieve that,” said Oomen.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.